All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
In a big news day for Duchenne muscular dystrophy (DMD) companies, Capricor Therapeutics Inc. CEO Linda Marbán told BioWorld that investors will "see news coming in the next week or two with a clearly delineated path to registration" for CAP-1002. "We have a trial design; we have a plan on what has to be done."